Gensight Biologics SA Stock
€0.36
Your prediction
Gensight Biologics SA Stock
Pros and Cons of Gensight Biologics SA in the next few years
Pros
Cons
Performance of Gensight Biologics SA vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Gensight Biologics SA | -1.090% | 1.961% | 2.680% | -43.566% | -17.833% | -95.220% | -68.014% |
India Globalization Capital | 5.300% | -5.442% | -17.262% | -27.979% | 6.107% | -78.779% | -74.028% |
Celsion Corp. | -6.440% | -3.077% | -19.915% | -6.436% | 58.824% | -92.500% | -95.825% |
Protara Therapeutics Inc. | 1.170% | 12.338% | -2.809% | 8.125% | 2.367% | -71.405% | - |
Comments
News
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Launches Newsletter for Retail Investors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal